TWi Pharmaceuticals Announced the Promotion of R&D EVP Jianbo Xie as COO

TAIPEI, May 14, 2015 -- TWi Pharmaceuticals, Inc. ("TWi") (Stock Ticker:4180.TT) announced that its R&D Executive Vice President (EVP) Mr. Jianbo Xie was promoted to Chief Operating Officer (COO) effective immediately.  The reorganization is intended for better efficiency and maximal output for TWi's team in Taiwan.  In addition to being responsible for his existing R&D function, Mr. Xie will also be responsible for Production in Chungli and Operations in Neihu headquarters.

With EVP & COO Jianbo Xie being responsible for Taiwan R&D and related operations, together with President & CEO Tina Guilderresponsible for commercialization, financial and corporate development, and overall operating performance, TWi will be moving toward another milestone; stronger R&D, growing commercialization, and a sustainable enterprise.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact:

Eric Lin
Investor Relations
Tel: +886-2-2657-3350 ext. 407
Email: [email protected]

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.